These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22989051)

  • 1. Effects of repeated intravitreal bevacizumab injections on the inner retinal function in neovascular age-related macular degeneration.
    Kim HD; Kim SH; Cho IH; Moon CH; Ohn YH; Park TK
    Acta Ophthalmol; 2013 Mar; 91(2):e154-6. PubMed ID: 22989051
    [No Abstract]   [Full Text] [Related]  

  • 2. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.
    Ahmadieh H; Taei R; Riazi-Esfahani M; Piri N; Homayouni M; Daftarian N; Yaseri M
    Retina; 2011 Oct; 31(9):1819-26. PubMed ID: 21555967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections.
    Mekjavic PJ; Kraut A; Urbancic M; Lenassi E; Hawlina M
    Acta Ophthalmol; 2011 Nov; 89(7):647-53. PubMed ID: 19860774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage.
    Treumer F; Roider J; Hillenkamp J
    Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
    Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW
    Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between foveal microstructure and visual outcome in age-related macular degeneration.
    Shin HJ; Chung H; Kim HC
    Retina; 2011 Sep; 31(8):1627-36. PubMed ID: 21606888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrasound assessment of ocular vascular effects of repeated intravitreal injections of ranibizumab for wet age-related macular degeneration.
    Bonnin P; Pournaras JA; Makowiecka K; Krivosic V; Kedra AW; Le Gargasson JF; Gaudric A; Levy BI; Cohen YS; Tadayoni R; Massin P
    Acta Ophthalmol; 2014 Aug; 92(5):e382-7. PubMed ID: 25043792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity.
    Axer-Siegel R; Bor E; Bourla DH; Weinberger D; Mimouni K
    Retina; 2012 Oct; 32(9):1811-20. PubMed ID: 22825407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Makalic E; Schmidt DF; Sandhu SS; Baird PN; Guymer RH
    Ophthalmology; 2013 Jan; 120(1):115-21. PubMed ID: 23149126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration.
    Gomi F; Sawa M; Tsujikawa M; Nishida K
    Retina; 2012 Oct; 32(9):1804-10. PubMed ID: 22718152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab in advanced-stage neovascular age-related macular degeneration with visual acuity lower than 20/200.
    Parodi MB; Cascavilla M; Papayannis A; Kontadakis DS; Bandello F; Iacono P
    Arch Ophthalmol; 2012 Jul; 130(7):934-5. PubMed ID: 22776937
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study.
    Holz FG; Amoaku W; Donate J; Guymer RH; Kellner U; Schlingemann RO; Weichselberger A; Staurenghi G;
    Ophthalmology; 2011 Apr; 118(4):663-71. PubMed ID: 21459217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retinal functional changes measured by microperimetry in neovascular age-related macular degeneration treated with ranibizumab.
    Cho HJ; Kim CG; Yoo SJ; Cho SW; Lee DW; Kim JW; Lee JH
    Am J Ophthalmol; 2013 Jan; 155(1):118-126.e1. PubMed ID: 23022163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
    Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
    Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab for neovascular age-related macular degeneration in China.
    Li X; Hu Y; Sun X; Zhang J; Zhang M;
    Ophthalmology; 2012 Oct; 119(10):2087-93. PubMed ID: 22818896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of fellow eye visual acuity on visual acuity of study eyes receiving ranibizumab for age-related macular degeneration.
    Zweifel SA; Saroj N; Shapiro H; Freund KB
    Retina; 2012 Jul; 32(7):1243-9. PubMed ID: 22466461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of wet age-related macular degeneration by ranibizumab in "real life" in France: treatment behaviours and associated visual outcome.
    Souied EH; Cohen SY; de Pouvourville G; Dupeyron G; Latour E; Ponthieux A; Weber M
    Acta Ophthalmol; 2015 Mar; 93(2):e179-80. PubMed ID: 25377519
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
    Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
    Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study.
    El-Mollayess GM; Mahfoud Z; Schakal AR; Salti HI; Jaafar D; Bashshur ZF
    Am J Ophthalmol; 2012 Mar; 153(3):481-489.e1. PubMed ID: 22014603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.